Recombinant HPV16 E6 protein [His]

Objectives: Using laser capture microdissection (LCM) and sensitive human papillomavirus (HPV) genotyping, we aimed to determine the distribution of vaccine-preventable types in cervical intraepithelial neoplasia grade 3 (CIN3) lesions and adenocarcinoma in situ (AIS) in young women in Victoria, Australia, offered catch-up HPV vaccination, as a baseline for ongoing vaccine impact monitoring. We also compared findings with available pre-vaccination estimates from women with HPV detected on concurrently-collected cytology samples. Methods: Consecutive histologically-confirmed CIN3/AIS biopsies were collected between May 2011 and December 2014 from vaccine-eligible women (born after 30th June 1981). Genotypes present in whole tissue sections (WTS) were determined by a sensitive reverse hybridisation assay; RHA kit HPV SPF10-LiPA25, v1 (Labo Bio-medical Products). Where multiple genotypes were detected, lesions were isolated using LCM and genotyped. Cervical cytology samples from a pre-vaccine cohort had been previously collected and genotyped using HPV Linear Array HPV Genotyping Test (Roche Diagnostics). Mixed-genotype detections in this cohort were resolved to single-lesion-attributable genotypes using hierarchical attribution. Results: Overall, 213 and 530 cases were included from pre- and post-vaccine time-periods, respectively. In 18-25 year-olds, the proportion of HPV16/18-positive CIN3/AIS decreased significantly over time from 69% in 2001-2005 (pre-vaccine), to 62% in 2011-2012 (post-vaccine), to 47% in 2013-2014 (p-trend = 0.004). There was no significant change in HPV16/18 in 26-32 year-olds (p-trend = 0.15). In 2013/14, nonavalent vaccine types accounted for 80% of CIN3/AIS in 18-25 year old women and 90% in 26-32 year old women. Conclusion: Four to 8 years following implementation of HPV vaccination in Australia, approximately 70% of CIN3/AIS in young women was due to HPV16/18. Our data, despite some limitations due to change in methods between pre- and post-vaccine periods, suggests that for vaccine-eligible women aged 18-25 at the time of biopsy, the proportion of HPV16/18-attributable CIN3/AIS lesions is significantly declining post-vaccination. Crown Copyright (C) 2020 Published by Elsevier Ltd. All rights reserved.

Aim This study aimed to evaluate knowledge, health belief, and preventive behavior regarding cervical cancer among Turkish Women. Subjects and methods This cross-sectional descriptive study was conducted from May to June 2019 in the province of Aydin, Turkey, with a total of 131 women. The data were collected using questionnaires filled out by the participants and the Cancer Information Overload Scale and The Turkish version of the Cervical Cancer and HPV Awareness Questionnaire. Data were analyzed using t test, ANOVA, and Pearson correlation analysis performed using the Statistical Package for Social Sciences version 20. Results It is seen from the results of the study that married women, women who have been sexually active before, and women who had at least one pregnancy had a higher Cancer Information Overload Scale score (p < 0.05). This study showed that 56.8% of participants had not undergone a Pap smear test. Women with active smoking were less likely than those without active smoking to have a perceived seriousness score (15.82 +/- 4.25 vs 18.19 +/- 4.56). Women who had a Pap smear test were more likely than those who had not had a Pap smear test to have a perceived seriousness score (19.78 +/- 3.61 vs 17.30 +/- 4.94). (p < 0.05). Conclusion There is a need for more participation in the Pap smear test. This study showed a high level of perceived seriousness increased Pap smear test screening. Aside from studies evaluating the knowledge and practice level of the population in cervical cancer, interventional studies promoting the development of preventive behaviors would contribute significantly to the literature.